Neuhauser Syndrome

- Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 9 studies at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, to be held in Madrid, Spain, from October 20-24. Continue Reading Lunit AI-powered TIL analyzer, Lunit SCOPE IO (PRNewsfoto/Lunit) During this year's congress, Lunit plans to highlight the predictive value and analytical power of its Lunit SCOPE suite, offering valuable insights for understanding the tumor microenvironment, predicting treatment responses, and accurately assessing HER2 scores, in various types of cancer such as biliary tract cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. A collaborative study indicated that AI-based immune phenotyping can predict therapy outcomes in advanced biliary tract cancer (BTC) patients who are planning to be treated with anti-PD-1 therapy. A total of 337 H&E-stained whole slide images (WSI) were acquired for assessment. In the study, the research team defined the immune phenotype of the WSI samples via Lunit SCOPE IO, Lunit's AI TIL (tumor-infiltrating lymphocytes) analyzer. Among the three immune phenotypes (inflamed; immune-excluded; immune-desert), the inflamed group showed enhanced overall survival (12.5 vs. 5.1 months), progression-free survival (5.0 vs. 2.0 months), and objective response rates (27.5% vs. 7.7%), compared to the non-inflamed group. In another study, it was found that TIL density in tumor microenvironment is highly correlated with favorable treatment response to immune checkpoint inhibitor (ICI) in head and neck squamous cell carcinoma (HNSCC). Assessed by Lunit SCOPE IO, patients with high-TIL showed a higher objective response rate (21.6% vs 5.7%) and more favorable median progression-free survival (3.2 vs 1.6 months). Lunit also plans to present the results of three trials during this year's congress. A joint trial with the Mayo Clinic unveils that epithelial TIL demonstrated the highest ability to distinguish between MMR-D (Mismatch repair deficiency) and MMR-P (Mismatch repair proficiency) tumors in colon cancer. The post-hoc exploratory analysis results of three clinical trials utilizing Lunit SCOPE IO in Italy and France are also set to be showcased. In another study, HER2 (human epidermal growth factor receptor-2) scoring in biliary tract cancer was evaluated using Lunit SCOPE HER2. The analysis showed a substantial concordance of 75.3% between AI and human pathologists' assessments. Another study aimed to predict multiple druggable mutations in non-small cell lung cancer (NSCLC) based on AI analysis of H&E images. More than 3,000 NSCLC samples were used as training data to develop an AI-powered predictive model. In validation in an independent dataset, the model showed robust performance in predicting six types of mutations (EGFR-mt, KRAS-mt, ALK-tr, ROS1-tr, RET-tr, MET-ex). Notably, for MET exon skipping mutations, the model achieved a high positive predictive value (PPV), showing that test-positive patients were three times more likely to have true-MET-ex positive mutations compared to the overall patient population. Moreover, specificity and PPV for identifying patients without mutations (All-WT) were 99.2% and 95.2% respectively, which means with AI assistance unnecessary tests can be avoided. Following the results, it is expected that the newly developed AI genotype predictor, available for multiple genotypes in non-small cell lung cancer, holds immense potential for widespread adoption by clinicians and pharmaceutical industry leaders globally. "We are thrilled to be at this year's ESMO with nine groundbreaking study results that prove the effectiveness of the Lunit SCOPE AI WSI analyzer and biomarker platform," said Brandon Suh, CEO of Lunit. "The study results emphasize the substantial progress made with Lunit SCOPE IO, building compelling evidence of the critical role of immune phenotyping in understanding cancer biology and optimizing treatment strategies. We remain committed to advancing this transformative technology through further research and development." For inquiries or to schedule a meeting with the Lunit team, please contact [email protected]. Lunit's Abstracts at ESMO 2023 About Lunit Lunit is a deep learning-based medical AI company on a mission to conquer cancer. Our focus is on developing AI solutions for precision diagnostics and therapeutics, ensuring the right diagnosis, and treatment, at the right cost for each patient. Lunit is devoted to developing advanced medical image analytics and AI-based biomarkers via cutting-edge technology. Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. As a medical AI company grounded on clinical evidence, the company's findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences, including ASCO and AACR. After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 2,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io About Lunit SCOPE Lunit SCOPE is a suite of AI-powered software that analyzes tissue slide images for digital pathology and AI biomarker development, aiming to optimize workflow and facilitate more accurate and predictive clinical data for clinicians and researchers. Lunit SCOPE platform offers multiple AI-powered tissue analysis products and assays that can streamline digital pathology workflow and diagnostics and enhance the drug development process. Lunit SCOPE IO analyzes the tumor microenvironment (TME) based on H&E analysis and provides AI-based predictive clinical outcome information. In addition, AI-driven Immunohistochemistry (IHC) slide analysis services are offered, through products such as Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others. SOURCE Lunit

GlaxoSmithKline (GSK) has announced that it has received approval from the US Food and Drug Administration (FDA) for Priorix, a live measles, mumps and rubella (MMR) vaccine. The vaccine can be used to immunise those aged 12 months and above to help prevent contracting measles, mumps and rubella. The treatment is currently licensed in more than 100 countries globally, including all European countries, Australia, New Zealand and Canada, with a roll-out of over 800 million doses to date. Measles, mumps and rubella are highly-contagious viral diseases and account for significant morbidity and mortality worldwide. More recently, increasing instances of measles outbreaks have been recorded in the US and globally, with over 400,000 cases confirmed in 2019, which marks a considerable regression in the decades of progress made towards the elimination of measles in many countries. Temi Folaranmi, vice president and vaccines therapeutic area head of US Medical Affairs at GSK said: “Outbreaks of measles in recent years demonstrate how quickly diseases can return without widespread immunisation. Missed vaccinations during the pandemic makes children even more vulnerable to vaccine-preventable diseases like measles. “Making Priorix available to patients in the US will ensure health care professionals have more than one option for this critical vaccine as they work to catch their patients up on recommended vaccinations,” he added. Outlined in a US Centers for Disease Control and Prevention (CDC) report, vaccine ordering in the past two years through the CDC’s Vaccines For Children programme – the federal programme which has facilitated the immunisation of about half of the children in the US – dropped by more than 10%, suggesting that fewer vaccinations in children were occurring. It was also highlighted that 400,000 fewer children were enrolled in kindergarten in the 2020-2021 school year than expected nationally, which means those children might be behind on childhood immunisations. The safety of Priorix was evaluated in six clinical studies, in which a total of 12,151 participants, including 6,391 in the US, were given at least one dose of the vaccine. The efficacy of Priorix was demonstrated based on immunogenicity data versus the comparator vaccine. With this approval, Priorix will offer US healthcare professionals another MMR vaccine choice. It may be administered as a first dose, followed up by a second dose of Priorix. It can also be administered as a second dose to individuals who have previously received the first dose of another MMR-containing vaccine.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones. COVID-19 Infection Doesn’t Seem to Confer Strong Antibody Response A new study out of Northwestern University published in Scientific Reports shows that previous exposure to SARS-CoV-2, the virus that causes COVID-19, doesn’t guarantee a high antibody response. It also suggests that a robust antibody response isn’t guaranteed after a single dose of the vaccine. The data supports full vaccination, even for people who caught COVID-19. The researchers tested blood samples from adults who tested positive for COVID-19 to evaluate how long the immunity benefits of the Pfizer-BioNTech and Moderna mRNA vaccines lasted and how well they protect against variants. The participants submitted blood samples two to three weeks after their first and second vaccine doses and two months after the second dose. “When we tested blood samples from participants collected about three weeks after their second vaccine dose, the average level of inhibition was 98%, indicating a very high level of neutralizing antibodies,” said Thomas McDade, a Northwestern biological anthropologist who worked with pharmacologist Alexis Demonbreun, on the study. They also tested emerging variants, including Alpha (UK), Beta (South Africa), and Gamma (Brazil). They found the inhibition levels to the variants were significantly lower, ranging from 67% to 92%. Testing samples two months after the second dose, the investigators found antibody responses dropped by approximately 20%. The people with clinically confirmed COVID-19 and multiple symptoms had a higher response level than people who tested positive but had mild symptoms or were asymptomatic. “Our study shows that prior exposure to SARSo-CoV-2 does not guarantee a high level of antibodies, nor does it guarantee a robust antibody response to the first vaccine dose,” McDade said. “For people who had mild or asymptomatic infections, their antibody response to vaccination is essentially the same as it is for people who have not been previously exposed.” Asymptomatic COVID-19 May Still Cause Damage A research study published in the Annals of Internal Medicine by Eric Topol and Daniel Oran from Scripps Research Translational Institute suggests that even asymptomatic COVID-19 infections may cause lung damage. The research began by evaluating data from patients aboard the cruise ship Diamond Princess which was quarantined off the coast of Japan in the earliest part of the pandemic. Of the 104 patients who tested positive on the ship, 76 were asymptomatic. However, CT scans found 54% had lung abnormalities known as ground glass opacities, which are indicative of fluid build-up in the lungs. It also included data from other parts of the world. Predicting Alzheimer’s Through a New Brain Model A study from investigators with Brigham and Women’s Hospital has the potential to predict Alzheimer’s progress. They created an induced pluripotent stem cell (iPSC) line from more than 50 different people that also had longitudinal clinical data, quantitative neuropathology data, and genetic and molecular brain tissue profiling. They turned the stem cells into brain cells and analyzed the molecular pathways of the living neurons in a Petri dish. They identified specific types of beta-amyloid and tau, both abnormal proteins associated with cognitive decline and Alzheimer’s, as well as signaling pathways that affected the production of the proteins. The people’s different genetic backgrounds created different profiles of beta-amyloid and tau, which are predictive in nature. Of interest as well is the possibility that antibody drugs against these proteins, such as Biogen’s aducanumab, may respond differently to different species of the proteins, the test may be used to determine what patients the drugs would be effective for. Using Electrical Stimulation to Speed Tendon Healing Researchers with the National University of Ireland Galway developed a device that assists tendon cell function and repair via electrical stimulation from an implantable device. In addition, the device is powered by body movement. The device uses a fabric-like mesh called piezoelectric material that generates electricity when stretched or placed under mechanical pressure. They can be tailored to individual patients or disorders. “Our discovery shows that an electrical charge is produced in the treatment target area — the damaged or injured tendon — when the implanted device is stretched during walking. The potential gamechanger here is like a power switch in a cell — the electrical stimulus turns on tendon-specific regenerative processes in the damaged tendon,” said Marc Fernandez, who carried out the principal research study at CURAM, the SFI Research Centre for Medical Devices based at NUI Galway. Identifying Proteins That Drive Glioblastoma Investigators at McGill University identified proteins that drive cancer stem cells, specifically galectin1. Glioblastoma is the most common and aggressive brain tumor in adults and is typically resistant to treatment. Surgery, radiation, and chemotherapy can ease symptoms for a few months, but the cancer cells usually regrow after treatment. The researchers found that by inhibiting the galectin1 protein, the brain tumors didn’t grow for several months. Galectin1 interacts with another protein, HOXA5, to control the pathways that drive cancer stem cell behavior. Suppressing galectin1 in preclinical models significantly improved tumor responses to radiation therapy and extended the lifespan of the animals they were working with. MMR and Tdap Vaccines Might Protect Against Severe COVID-19 A study out of Brigham and Women’s Hospital suggests that the childhood vaccines for Measles-Mumps-Rubella (MMR) and Tetanus-Diphtheria-Pertussis (Tdap) may prevent severe COVID-19. They theorize these vaccines might generate cross-reactive memory T cells that respond to antigens to a few microorganisms, including the viral antigens in SARS-CoV-2. They analyzed T cell responses to antigens from the blood of COVID-19 convalescent patients as well as patient vaccinated against COVID-19 and compared them to antigens from SARS-CoV-2 and the MMR and Tdap vaccines. Working with Cleveland Clinic, they pulled data from a cohort of COVID-19 patients that found previous MMR or Tdap vaccinated was linked to decreased disease severity. Patients previously vaccinated for MMR had a 38% decrease in hospitalization and a 32% decrease in ICU admission and death. Patients who received the Tdap had 23% and 20%, respectively, for hospitalization and ICU admission and death. “Our Cleveland Clinic colleagues observed an association where individuals with COVID-19 who had either MMR or Tdap vaccines had a much lower frequency of going to the intensive care unit or dying,” said co-author Andrew Lichtman, immunology and senior investigator in the Brigham and Women’s Hospital Department of Pathology and Professor of Pathology at Harvard Medical School. “Although previous smaller studies suggested a similar link, our in-depth epidemiological analyses, together with our basic research results, suggest that these commonly given vaccines may protect against severe disease.”